Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sargramostim for COVID-19 acute hypoxic respiratory failure
2020-001254-22Phase 4Completed
- Sponsor
- Ghent University Hospital
- Start
- Mar 2020
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial in coronavirus disease 2019 (COVID-19) and Acute hypoxaemic respiratory failure (AHRF) comparing Sargramostim plus standard of care with Standard of care control (2 arms). Primary endpoints: Change in oxygenation after 5 days and P(A-a)O2 gradient after 5 days. Started Mar 2020; status: completed.
02
Drugs
sargramostim
03
Conditions
coronavirus disease 2019 (COVID-19)Acute hypoxaemic respiratory failure (AHRF)
Beyond the preview
Go deeper on 2020-001254-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-001254-22.